Kevin G. Shaw

CIK: 0001953666

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

NXTC

NextCure, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (2 total)

NXTC
NextCure, Inc.
Jan 30, 2026
Award(A)
Employee Stock Option (Right to Buy)
Direct
8.3K shares-
NXTC
NextCure, Inc.
Jan 31, 2025
Award(A)
Employee Stock Option (Right to Buy)
Direct
66.1K shares-

		Type	Shares	Price		Ownership
Jan 30, 2026	NXTC NextCure, Inc.	Award(A) Employee Stock Option (Right to Buy)	8,270	-	-	Direct
Jan 31, 2025	NXTC NextCure, Inc.	Award(A) Employee Stock Option (Right to Buy)	66,125	-	-	Direct

1-2 of 2 transactions

About Shaw Kevin G.

Shaw Kevin G. (SEC CIK 0001953666) files insider reports with the SEC as Sr VP, General Counsel of NextCure, Inc. (NXTC).

Signal8 holds 2 ownership filings by Shaw Kevin G., all Form 4s, filed between Feb 3, 2025 and Feb 3, 2026. Those filings report 2 transactions, from Jan 31, 2025 to Jan 30, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Shaw Kevin G.'s filings is in BELTSVILLE, MD.

Recent filings by Shaw Kevin G.

Jan 30, 2026: Grant or award of NXTC derivative securities (Form 4, code A).
Jan 31, 2025: Grant or award of NXTC derivative securities (Form 4, code A).

Other insiders filing for NextCure, Inc. (NXTC)

ADAR1 Capital Management, LLC, 10% Owner
Simcere Zaiming, Inc., Officer
Feigal Ellen, Director
Jones Elaine V, Director
Borgman Anne Elizabeth, Director
Webster Stephen W, Director

How to read Form 4 transaction codes